Developmental biology

DGAP-News: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 12:08pm

NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.

Key Points: 
  • NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 11:30am

In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.

Key Points: 
  • In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development

Tuesday, September 21, 2021 - 1:35pm

HAMILTON, ONandBOSTON, Sept. 21, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development.

Key Points: 
  • HAMILTON, ONandBOSTON, Sept. 21, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development.
  • To that end, Eric brings to our team deep business development and corporate strategy experience, combined with a scientific and finance background."
  • Prior to Vicarius, he was chief business officer of Genocea Biosciences where he led business development, alliance management and commercial operations.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.

Pew Funds Six Teams to Advance Innovative Biomedical Research

Wednesday, September 15, 2021 - 3:00pm

These scientistsalumni of Pew's biomedical programs in the United States and Latin Americawill partner on interdisciplinary research to tackle some of the most pressing questions in human biology and disease.

Key Points: 
  • These scientistsalumni of Pew's biomedical programs in the United States and Latin Americawill partner on interdisciplinary research to tackle some of the most pressing questions in human biology and disease.
  • "The COVID-19 pandemic has underscored the critical role innovative biomedical research plays in addressing global health problems," said Molly Irwin, vice president for research and science at The Pew Charitable Trusts.
  • For more than 35 years, Pew has encouraged collaboration among its diverse community of biomedical scientists, culminating in the launch of the Innovation Fund in 2017.
  • The fund's award criteria were developed to promote synergy among program alumni, motivating researchers to collaborate on new proposals.

Spikimm and Institut Pasteur Announce That SPKM001, A Next-generation, Highly Potent Anti-SARS-CoV-2 Human Monoclonal Antibody, Effectively Neutralizes the Delta and Delta Plus Variants

Wednesday, September 8, 2021 - 9:00am

SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein.

Key Points: 
  • SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the SARS-CoV-2 Spike protein.
  • SpikImm has recently signed an exclusive worldwide license agreement with the Institut Pasteur for the development of anti-SARS-CoV-2 (Covid-19) monoclonal antibodies (mAbs), including SPKM001.
  • Delta Plus, which the World Health Organization also lists as a variant of concern, was first detected in the U.K. in June.
  • It has since been found in several other countries, including the U.S., India, China, Russia, and Japan.

Vizgen Releases Commercial MERSCOPE Platform

Monday, August 30, 2021 - 11:00am

Vizgen will continue shipping a limited number of commercial instruments for the next several months before releasing MERSCOPE to the U.S. market at large in late 2021.

Key Points: 
  • Vizgen will continue shipping a limited number of commercial instruments for the next several months before releasing MERSCOPE to the U.S. market at large in late 2021.
  • View the full release here: https://www.businesswire.com/news/home/20210830005191/en/
    Vizgen releases MERSCOPE Platform to leading research institutes.
  • MERSCOPE is the first commercially available high-plex, single-cell spatial genomics platform for spatially profiling gene expression across whole tissues and resolving individual transcripts with nanometer-scale resolution.
  • (Photo: Business Wire)
    MERSCOPE is the first commercially available high-plex single-cell spatial genomics platform, and the only platform for MERFISH technology.

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

Tuesday, August 3, 2021 - 1:00pm

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:

Key Points: 
  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:
    2021 Wedbush PacGrow Healthcare Virtual Conference, panel: So Let it Be (Re)Written - Updates in Gene Modulation at 9:10 a.m.
  • ET on Tuesday, August 10
    Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.
  • Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
  • Magenta is based in Cambridge, Mass.

Cellino Appoints Industry Pioneer Robert J. Palay to the Board

Tuesday, August 3, 2021 - 1:00pm

Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.

Key Points: 
  • Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20210803005032/en/
    Mr. Palay is one of the pioneers of the induced pluripotent stem cell (iPSC) industry.
  • "We are pleased to welcome Robert to the Cellino Board," said Nabiha Saklayen, Ph.D, CEO & Co-Founder, Cellino.
  • "I am thrilled to join the Cellino Board," said Robert J. Palay.

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Tuesday, July 27, 2021 - 12:00pm

Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).

Key Points: 
  • Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).
  • A single infusion in the treatment group consists of 200 million stem cells, or approximately 1.2 billion stem cells per patient over the course of study.
  • HBSCRF remains the only organization globally to administer pure, fresh mesenchymal stem cells, an adult stem cell harvested from fat, in such high quantities over repeat treatments.
  • Clinical trial authorizations encompass COVID-19 prevention and treatment , traumatic brain injury , Parkinsons disease , and multiple sclerosis.

InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment

Monday, July 26, 2021 - 1:00pm

This newly-released research paper, titled First Immunohistochemical Evidence of Human Tendon Repair Following Stem Cell Injection: A Case Report and Review of Literature , was published in the World Journal of Stem Cells on July 23, 2021 (DOI: https://dx.doi.org/10.4252/wjsc.v13.i7.944 ).

Key Points: 
  • This newly-released research paper, titled First Immunohistochemical Evidence of Human Tendon Repair Following Stem Cell Injection: A Case Report and Review of Literature , was published in the World Journal of Stem Cells on July 23, 2021 (DOI: https://dx.doi.org/10.4252/wjsc.v13.i7.944 ).
  • The analysis strongly indicates regenerative healing of the tendon, resulting from transformation of UA-ADRCs into new tendon tissue.
  • Importantly, the investigated tendon showed evidence of histological regeneration without scar formation, a finding indicating significant advantages over existing treatments options.
  • The microscopic images of the tendon treated with stem cells clearly demonstrate that a different type of healing had taken place.